Vistagen Therapeutics financials
$0.2980+0.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 | FY21 Mar 31 | FY20 Mar 31 | FY19 Mar 31 | FY18 Mar 31 | FY17 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $486.0K | $1.1M | -$227.0K | $1.1M | $1.1M | $0.00 | — | — | $1.3M |
| Gross profit | $1.3M | $486.0K | $1.1M | -$227.0K | $1.1M | $1.1M | $0.00 | — | — | $1.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | 100.0% |
| Operating income | -$72.1M | -$56.0M | -$33.0M | -$59.3M | -$47.8M | -$17.9M | -$20.8M | -$24.6M | -$14.2M | -$10.2M |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M | -$48.7M | -$42.3M | -$22.0M | -$25.7M | -$15.6M | -$11.6M |
| Net margin | −5491.3% | −10579.8% | −2759.6% | 26100.4% | −4392.4% | −3884.3% | — | — | — | −929.9% |
| Diluted EPS | $-1.83 | $-1.67 | $-1.52 | $-8.51 | $-7.38 | $-14.70 | $-15.00 | $-27.00 | $-33.60 | $-46.20 |
| EBITDA | -$71.9M | -$55.8M | -$32.9M | -$59.1M | -$47.1M | -$17.8M | -$20.6M | -$24.5M | -$14.1M | -$10.1M |
| Operating cash flow | -$66.4M | -$42.1M | -$25.8M | -$49.7M | -$45.2M | -$12.1M | -$15.8M | -$14.5M | -$9.1M | -$7.3M |
| Free cash flow | -$66.6M | -$42.3M | -$25.9M | -$50.5M | -$45.4M | -$12.3M | -$15.8M | -$14.7M | -$9.1M | -$7.5M |
| Diluted shares | 38.1M | 30.9M | 19.4M | 7.0M | 6.6M | 2.9M | 1.5M | 1.0M | 0.5M | 0.3M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.8M | $67.1M | $119.2M | $16.6M | $68.1M | $103.1M |
| Short-term investments | $14.6M | $13.4M | $0.00 | $0.00 | $0.00 | — |
| Total debt | $96.0K | $0.00 | $0.00 | $105.0K | $0.00 | $3.0K |
| Total assets | $48.6M | $84.3M | $123.7M | $21.1M | $74.6M | $108.3M |
| Total liabilities | $13.0M | $14.0M | $9.4M | $9.0M | $9.9M | $16.3M |
| Shareholders' equity | $35.5M | $70.4M | $114.3M | $12.1M | $64.7M | $92.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology